Cargando…

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants

BACKGROUND: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 Å from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the prime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Steven J., Pauly, Gary T., Akram, Aamir, Melody, Kevin, Rai, Ganesha, Maloney, David J., Ambrose, Zandrea, Thomas, Craig J., Schneider, Joel T., Hughes, Stephen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754833/ https://www.ncbi.nlm.nih.gov/pubmed/26880034 http://dx.doi.org/10.1186/s12977-016-0244-2

Ejemplares similares

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012)

Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice
por: Melody, Kevin, et al.
Publicado: (2020)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay
por: Smith, Steven J., et al.
Publicado: (2021)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
por: Dwivedi, Richa, et al.
Publicado: (2022)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Structure‐based non‐nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants
por: Smith, Steven J., et al.
Publicado: (2020)

Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus
por: Wei, Lei, et al.
Publicado: (2017)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Room-Temperature, Copper-Free Sonogashira Reactions Facilitated by Air-Stable, Monoligated Precatalyst [DTBNpP] Pd(crotyl)Cl
por: Pohida, Katherine, et al.
Publicado: (2018)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

The development of an effective synthetic route of rilpivirine
por: Zhang, Tao, et al.
Publicado: (2021)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013)

Disassembling the Nature of Capsid: Biochemical, Genetic, and Imaging Approaches to Assess HIV-1 Capsid Functions
por: Ingram, Zachary, et al.
Publicado: (2021)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
por: Pereira, Mariana, et al.
Publicado: (2023)

Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies
por: Rai, Ganesha, et al.
Publicado: (2014)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
por: Sculier, Delphine, et al.
Publicado: (2017)

Observational cohort study of rilpivirine (RPV) utilization in Europe
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2022)

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
por: Kovarova, Martina, et al.
Publicado: (2015)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Synthesis and evaluation of potent yaku'amide A analogs
por: Lo, Concordia C. L., et al.
Publicado: (2022)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors
por: Legoabe, Lesetja J, et al.
Publicado: (2015)

8-cyanobenzothiazinone analogs with potent antitubercular activity
por: Zhang, Gang, et al.
Publicado: (2021)

Structural Optimization of BIPPO Analogs as Potent Antimalarials
por: Zheng, Yang, et al.
Publicado: (2023)

Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine
por: Singh, Abhimanyu K., et al.
Publicado: (2022)

Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
por: Kovarova, Martina, et al.
Publicado: (2015)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

CG Dinucleotide Removal in Bioluminescent and Fluorescent Reporters Improves HIV-1 Replication and Reporter Gene Expression for Dual Imaging in Humanized Mice
por: Roy, Chandra N., et al.
Publicado: (2021)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less
por: Lucantoni, Federico, et al.
Publicado: (2022)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
por: Zhang, Chun, et al.
Publicado: (2023)

A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology
por: Kagan, Amanda B., et al.
Publicado: (2022)

Pentafluorosulfanyl-containing Triclocarban Analogs with Potent Antimicrobial Activity
por: Pujol, Eugènia, et al.
Publicado: (2018)

The nucleoside analog clitocine is a potent and efficacious readthrough agent
por: Friesen, Westley J., et al.
Publicado: (2017)

Synthesis of Chromen-4-One-Oxadiazole Substituted Analogs as Potent β-Glucuronidase Inhibitors
por: Taha, Muhammad, et al.
Publicado: (2019)

4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a Potent Inhibitor of Bacterial Phosphopantetheinyl Transferase That Attenuates Secondary Metabolism and Thwarts Bacterial Growth
por: Foley, Timothy L., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k5kr8bmc4q7rfokfo6olbdhd79